CONCORDBIO IN EQUITY
loading…—
Day range—
52-week range—
Market cap—
P/E · TTM—
As of—
| CUSTOMER | BASIS | EST ₹CR | RANGE | % REV | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| Business | REV SHARE | 1,080 | 1,080–1,080 | 90.0% | — | FY25 | DISC | 90% |
| “Details of business activities (accounting for 90% of the turnover) Sr. No. Description of Main Activity Description of Business Activity % of Turnover of the …” AR DOC | ||||||||
| Business | REV SHARE | 950 | 950–950 | 90.0% | COGS | FY26 | DISC | 90% |
| “Details of business activities (accounting for 90% of the turnover): S. No. Description of Main Activity Description of Business Activity % of Turnover of the …” AR DOC | ||||||||
| JSLJindal Stainless Ltd. | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “He has served as an Independent Director on the Board of Concord Biotech Limited since June 2022, and previously served in the same capacity at Jindal Stainles…” AR DOC | ||||||||
| United States | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “However, the newly announced United States tariff policy may increase costs associated with Indian exports to the United States, thereby affecting profit margi…” AR · +1 DOC | ||||||||
| China. | UNSTATED | — | — | — | COGS | FY26 | EST | 75% |
| “While India has earned its position as the “pharmacy of the world” through large-scale formulation exports, China continues to dominate global API manufacturin…” AR · +1 DOC | ||||||||
| Others | CONTRACT | CT 8 | — | — | — | FY26 | EST | 75% |
| “In outside India, company separately disclosed sales to America and Others.” AR · +2 DOC | ||||||||
| Parties | UNSTATED | — | — | — | — | FY25 | EST | 75% |
| “PARTICULARS OF CONTRACTS OR ARRAGEMENTS WITH RELATED PARTIES During the financial year, all related party transactions entered into by the Company were conduct…” AR DOC | ||||||||
| China. | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “The China-plus-one strategy has opened new avenues for Indian manufacturers, including Concord, who meet the stringent quality and compliance standards demande…” AR DOC | ||||||||
| Financial Year | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “DURING THE FINANCIAL YEAR: During the year under review, the Company has not made any application before the National Company Law Tribunal under Insolvency and…” AR · +1 DOC | ||||||||
| Office | CONTRACT | CT 1 | — | — | SG&A | FY26 | EST | 70% |
| “Details of material contracts or arrangement or transactions at arm’s length basis: Name of Related Party Nature of Relationship Nature of Contract / Arrangeme…” AR · +1 DOC | ||||||||
| Securities and Exchange Board of India | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “(f ) The Securities and Exchange Board of India (Registrar to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing wit…” AR · +1 DOC | ||||||||
| Business | UNSTATED | — | — | — | R&D | FY26 | EST | 70% |
| “THE RISE OF INDIAN CDMO BUSINESS One of the most significant beneficiaries of these macro- level changes is the Indian Contract Development and Manufacturing O…” AR DOC | ||||||||
| United States | UNSTATED | — | — | — | COGS | FY25 | EST | 70% |
| “By strengthening our relationship with Palvella, we aim to expand our footprint in global markets and enhance our supply chain for innovative, high-value produ…” AR DOC | ||||||||
| China. | UNSTATED | — | — | — | R&D | FY25 | EST | 70% |
| “The Indian Contract Development and Manufacturing Organisation (CDMO) sector is expected to thrive as international companies seek dependable alternatives to C…” AR DOC | ||||||||
| Others | CONTRACT | CT 4 | — | — | COGS | FY25 | EST | 70% |
| “Less : Adjustment made to contract price on account of: Provision for Sales Return (215.05) (2,853.11) Others - rate difference (175.65) (21.23) Total 1,20,008…” AR DOC | ||||||||
| FY27 | UNSTATED | — | — | — | — | FY27 | EST | 65% |
| “Our export business remained a key growth driver with export revenues increasing 46% year- on-year in Q1 FY27.” CONCALL DOC | ||||||||
| Australia | UNSTATED | — | — | — | COGS | 2025-11 | EST | 65% |
| “Ankur Vaid: It is difficult to quantify because when we supply the API to our domestic formulation customers, they make the formulations and cater to global ma…” CONCALL DOC | ||||||||
| CDSLCentral Depository Services (India) Ltd. | UNSTATED | — | — | — | — | FY26 | EST | 60% |
| “3) Now enter your User ID a. For CDSL: 16 digits beneficiary ID, b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID, c. Shareholders holding shares …” AR · +1 DOC | ||||||||
| SUPPLIER | BASIS | EST ₹CR | RANGE | % COST | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| Financial Year | UNSTATED | — | — | — | COGS | FY25 | EST | 75% |
| “Percentage of input material (inputs to total inputs by value) sourced from suppliers: FY 2025-26 Current Financial Year FY 2024-25 Previous Financial Year Dir…” AR DOC | ||||||||
| China. | UNSTATED | — | — | — | — | FY25 | EST | 70% |
| “USA policy updates for the Indian pharma industry Bio-Secure Act: Alongside domestic growth, the industry is also adapting to global regulatory changes, such a…” AR DOC | ||||||||
| SOURCE | READ | % | LAST READ |
|---|---|---|---|
| ANNUAL | 2/2 | 100% | 15-OCT-26 |
| CONCALL | 5/5 | 100% | 10-NOV-26 |
| SCREENER | 1/1 | 100% | 10-NOV-26 |
| SIGNAL | VALUE | AS OF | INPUTS |
|---|---|---|---|
| CUST MOM 1M | +5.1% | 14-NOV-26 | from 15-OCT-26 · Jindal Stainless Ltd. -1.7% w 1 · Central Depository Services (India) Ltd. +11.9% w 1 |
| DISTRESS SCORE | 0.043 | 13-OCT-26 | roe 0.13 · operatingMargin 0.35 · debtToEquity 0 · interestCoverage 346 · assetTurnover 0.47 · leverage 1.11 |
| TOP 10 CUSTOMERS % REV | 48.2% | 31-MAR-26 | sentence Our reliance on the top 10 customers has reduced from 48.2% in FY21 to approximately 37.6% in FY26, demonstrating consistent progress in diversification and the creation of a more resilient revenue base. · documentId 4,560 |